RxDoctor Payments Data

Siri Kunchakarra, MD

Magnetic Resonance Imaging (MRI) · Fresno, CANPI 1114212370

Payments from drug & device makers

$1,362in general payments, 2019–2025

Across 66 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$405
  • Johnson & Johnson$109
  • Abiomed$107
  • Alnylam Pharmaceuticals Inc.$79
  • Novartis$73
  • Actelion Pharmaceuticals US, Inc.$61
  • plus $529 from 17 others

What the payments were for

  • Food & beverage$1,362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few magnetic resonance imaging (mri) providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$210,662
Medicare patients
1,407
Services billed
3,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$127,286
EliquisApixaban113$120,897
EntrestoSacubitril/Valsartan81$118,935
Repatha SureclickEvolocumab17$20,350
XareltoRivaroxaban14$15,964
Metoprolol Succinate209$4,480
Atorvastatin Calcium230$3,276
Spironolactone172$1,232
Rosuvastatin Calcium60$1,229
Losartan Potassium91$787
Ezetimibe18$774
Carvedilol85$541
Furosemide84$464
Isosorbide Mononitrate ErIsosorbide Mononitrate34$430
Amlodipine Besylate94$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$405$127,286100 claims
PfizerEliquis$34$120,897113 claims
NovartisEntresto$73$118,93581 claims
Johnson & JohnsonXarelto$109$15,96414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few magnetic resonance imaging (mri) providers in Californiaon file to place this against a meaningful peer group, so we don't.

Where these figures come from

Is this you, or does something look wrong? →